ERPY - ERPY STOCK NEWS

ERYP released its monthly update on voting rights and shares as of June 30, 2022. The total share capital consists of 31,018,553 shares, with 32,520,107 gross voting rights and 32,517,607 net voting rights after accounting for treasury shares. These figures reflect stability in the company's voting rights framework, reassuring shareholders about their governance participation.

On June 24, 2022, ERYTECH Pharma held its Annual General Meeting, where all recommended resolutions were adopted. Key approvals included the annual financial statements for 2021, compensation policies for executive officers, and the share subscription options plan. The Board of Directors' authority to issue shares and grant free shares to officers was also authorized. ERYTECH develops innovative therapies using red blood cells and focuses on treatments for severe cancer forms. The company’s lead product, eryaspase, targets cancer cell metabolism, having received Fast Track designation from the FDA.

Monthly Voting Rights Update - As of May 31, 2022, the total number of shares comprising the share capital stands at 31,018,553. The total gross voting rights are reported at 32,518,547, while the net voting rights are 32,516,047. This information complies with the regulations set forth by the French Autorité des Marchés Financiers.

The data is crucial for assessing shareholder influence and voting power in the company's governance.

ERYTECH announced the availability of documents for its Annual General Meeting scheduled for June 24, 2022, in Paris. Shareholders can participate by attending in person, voting by mail or internet via the secure platform Votaccess, or granting proxy to a representative. The notice of meeting, including agenda and draft resolutions, is published and accessible on the company's website. ERYTECH, focused on cancer therapy through its ERYCAPS platform, is developing eryaspase, targeting cancer cell metabolism with FDA Fast Track designation for multiple indications.

ERYTECH Pharma announced that its CEO, Gil Beyen, will present at the H.C. Wainwright Global Investment Conference from May 23-26, 2022, in Miami, USA. The presentation is scheduled for May 25 at 10:30am ET, and it will be available online post-event. Beyen will also hold one-on-one meetings with investors on May 24-26. ERYTECH focuses on innovative therapies for severe cancers using its ERYCAPS® platform. The company’s lead candidate, eryaspase, recently showed positive results in trials for acute lymphoblastic leukemia and pancreatic cancer.

The monthly report dated April 30, 2022, highlights the total number of shares and voting rights for Erytech Pharma, listed on Euronext Paris and Nasdaq. As of April 30, 2022, there are 31,018,553 shares in total, with 32,518,547 gross voting rights and 32,516,047 net voting rights. The figures show consistency over recent months, reflecting stable capital structure without any significant changes that could affect shareholder interests.

ERYTECH Pharma, a clinical-stage biopharmaceutical firm, reported significant business developments for Q1 2022. The company sold its U.S. cell therapy manufacturing facility to Catalent for $44.5 million, boosting its cash position to approximately EUR 55 million. This transaction extends its cash runway until mid-2024. Key milestones include progress toward BLA submission for GRASPA® in treating acute lymphoblastic leukemia (ALL) patients with hypersensitivity to pegylated asparaginase, alongside positive data from ongoing clinical trials. The company aims to leverage its ERYCAPS® platform for future growth.

ERYTECH has filed its 2021 Universal Registration Document and Annual Report on Form 20-F with the AMF and SEC. These filings, accessible via the company's website, include a management report and financial data. Key dates in the 2022 financial calendar include the first quarter business update on May 12, the shareholders' meeting on June 24, and other quarterly updates throughout the year. ERYTECH specializes in red blood cell-based therapies targeting severe cancers and orphan diseases, with their lead candidate, eryaspase (GRASPA), showing promise in clinical trials.

ERYTECH has announced the sale of its U.S. manufacturing facility to Catalent for $44.5 million. This transaction is anticipated to lower ERYTECH's operating expenses and extend its cash runway to mid-2024, increasing cash reserves to approximately €55 million (or $60 million). A long-term supply agreement for the clinical and commercial supply of ERYTECH’s lead product, eryaspase (GRASPA®), will also be established with Catalent. ERYTECH is exploring strategic options to leverage its ERYCAPS® platform and capabilities.